Citations

Clear

959 citation(s) found for "Service, F J".

Zero fluoroscopy approach versus fluoroscopy approach for cardiac arrhythmia ablations: A systematic review and meta‐analysis
Kanitsoraphan, Chanavuth , Techorueangwiwat, Chol, Kewcharoen, Jakrin , Ayinapudi, Karnika , Bunch, T. Jared , Groh, Christopher A. , Navaravong, Leenhapong , Kewcharoen, Jakrin , Navaravong, Leenhapong , Kanitsoraphan, Chanavuth , Rattanawong, Pattara

Mayo Clinic

Journal of Cardiovascular Electrophysiology | August 24, 2021 | Volume: 32 | Issue: 10 | Pages: 2761-2776

10.1111/jce.15221 | PMID 34427955 Get It

AbstractBackgroundRadiofrequency catheter ablation for cardiac arrhythmias has traditionally been guided by fluoroscopy. Fluoroscopy exposes the patient, operator, and staff to ionizing radiation which has no safe dose void of stochastic and deterministic biologic risks. Zero fluoroscopy (ZF) approaches for catheter ablation have been advocated to eliminate these risks. We conducted a meta‐analysis comparing acute procedure success, recurrence‐free survival, complications, and procedure times between the approaches.MethodsWe conducted a literature search from inception through December 2020 in the databases of EMBASE and MEDLINE. We included randomized controlled trials and cohorts that compared the outcomes of interest in ZF and conventional/low fluoroscopy (CF/LF) approaches. The outcomes sought were acute procedure success, recurrence‐free survival, complications, and procedure times. Effect estimates were combined, using the random‐effects, generic inverse variance method of DerSimonian and Laird.ResultsSixteen studies from 2013 to 2020, including 6052 patients (2219 ZF, 3833 CF/LF) were included. There were no significant differences in acute procedure success rate (odds ratio [OR]: 1.10, 95% confidence interval [CI]: 0.75–1.59), recurrence‐free survival (OR: 1.08, 95% CI: 0.78–1.49), periprocedural complication rate (OR: 0.72, 95% CI: 0.45–1.16), or total procedure time (weighted mean difference 2.32 min, 95% CI: −2.85–7.50) between ZF and CF/LF approaches, respectively. Overall, only 1.26% of patients crossed over from ZF to CF/LF arm.ConclusionsPeriprocedural and postprocedural outcomes with a ZF approach compared favorably with traditional fluoroscopic guidance without increasing procedural times. As comfort with ZF grows, coupled with evolving mapping technologies, this method has potential to become the standard approach for catheter ablation.
Risk factors and outcomes of post‐transplant erythrocytosis among adult kidney transplant recipients: a systematic review and meta‐analysis
Mekraksakit, Poemlarp , Boonpheng, Boonphiphop , Leelaviwat, Natnicha , Duangkham, Samapon, Deb, Anasua , Kewcharoen, Jakrin , Nugent, Kenneth , Cheungpasitporn, Wisit , Cheungpasitporn, Wisit , Mekraksakit, Poemlarp , Kewcharoen, Jakrin

Mayo Clinic

Transplant International | August 19, 2021 | Volume: 34 | Issue: 11 | Pages: 2071-2086

10.1111/tri.14016 | PMID 34412165 Get It

Sex-Specific Effects of Plastic Caging in Murine Viral Myocarditis
Bruno, Katelyn A. , Macomb, Logan P. , Morales-Lara, Andrea Carolina , Mathews, Jessica, Frisancho, J. Augusto, Yang, Alex Lingyun, Florio, Damian N. Di , Edenfield, Brandy , Whelan, Emily R. , Salomon, Gary R., Hill, Anneliese R., Hewa‐Rahinduwage, Chathuranga C., Scott, Ashley Jennie , Greyner, Henry, Molina, Frank, Greenaway, Merci S., Cooper, George , Fairweather, DeLisa , Morales-Lara, A Carolina, Mathews, Jessica E, Yang, Alex L, Di Florio, Damian N, Edenfield, Brandy H, Fairweather, DeLisa , Bruno, Katelyn A , Di Florio, Damian N , Cooper, George M.

Mayo Clinic

International Journal of Molecular Sciences | August 17, 2021 | Volume: 22 | Issue: 16 | Pages: 8834

10.3390/ijms22168834 | PMID 34445539 Get It

Background: Myocarditis is an inflammatory heart disease caused by viral infections that can lead to heart failure, and occurs more often in men than women. Since animal studies have shown that myocarditis is influenced by sex hormones, we hypothesized that endocrine disruptors, which interfere with natural hormones, may play a role in the progression of the disease. The human population is exposed to the endocrine disruptor bisphenol A (BPA) from plastics, such as water bottles and plastic food containers. Methods: Male and female adult BALB/c mice were housed in plastic versus glass caging, or exposed to BPA in drinking water versus control water. Myocarditis was induced with coxsackievirus B3 on day 0, and the endpoints were assessed on day 10 post infection. Results: We found that male BALB/c mice that were exposed to plastic caging had increased myocarditis due to complement activation and elevated numbers of macrophages and neutrophils, whereas females had elevated mast cell activation and fibrosis. Conclusions: These findings show that housing mice in traditional plastic caging increases viral myocarditis in males and females, but using sex-specific immune mechanisms.
TCF7L2 Genetic Variants Do Not Influence Insulin Sensitivity or Secretion Indices in Autoantibody-Positive Individuals at Risk for Type 1 Diabetes
Redondo, María J. , Warnock, Megan, Libman, Ingrid , Bocchino, Laura E., Cuthbertson, David , Geyer, Susan, Pugliese, Alberto , Steck, Andrea K. , Becker, Dorothy J., Sosenko, Jay M. , Bacha, Fida , Group, the Type 1 Diabetes TrialNet Study, Evans‐Molina, Carmella , Group, the Type 1 Diabetes TrialNet Study

Mayo Clinic

Diabetes Care | July 29, 2021 | Volume: 44 | Issue: 9 | Pages: 2039-2044

10.2337/dc21-0531 | PMID 34326068 Get It

OBJECTIVE We aimed to test whether type 2 diabetes (T2D)–associated TCF7L2 genetic variants affect insulin sensitivity or secretion in autoantibody-positive relatives at risk for type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS We studied autoantibody-positive TrialNet Pathway to Prevention study participants (N = 1,061) (mean age 16.3 years) with TCF7L2 single nucleotide polymorphism (SNP) information and baseline oral glucose tolerance test (OGTT) to calculate indices of insulin sensitivity and secretion. With Bonferroni correction for multiple comparisons, P values < 0.0086 were considered statistically significant. RESULTS None, one, and two T2D-linked TCF7L2 alleles were present in 48.1%, 43.9%, and 8.0% of the participants, respectively. Insulin sensitivity (as reflected by 1/fasting insulin [1/IF]) decreased with increasing BMI z score and was lower in Hispanics. Insulin secretion (as measured by 30-min C-peptide index) positively correlated with age and BMI z score. Oral disposition index was negatively correlated with age, BMI z score, and Hispanic ethnicity. None of the indices were associated with TCF7L2 SNPs. In multivariable analysis models with age, BMI z score, ethnicity, sex, and TCF7L2 alleles as independent variables, C-peptide index increased with age, while BMI z score was associated with higher insulin secretion (C-peptide index), lower insulin sensitivity (1/IF), and lower disposition index; there was no significant effect of TCF7L2 SNPs on any of these indices. When restricting the analyses to participants with a normal OGTT (n = 743; 70%), the results were similar. CONCLUSIONS In nondiabetic autoantibody-positive individuals, TCF7L2 SNPs were not related to insulin sensitivity or secretion indices after accounting for BMI z score, age, sex, and ethnicity.
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration
Auclair, Daniel , Adam, Stacey J. , Agarwal, Amit , Anderson, Melissa , Bustoros, Mark , Chapman, Jessica R. , Connors, Dana E. , Dash, Ajeeta B. , Bacco, Alessandra Di , Ling, Du, Flores‐Montero, Juan , Ghobrial, Irene M. , Gormley, Nicole , Gupta, Ira, Higley, Howard R., Hillengaß, Jens , Kanapuru, Bindu , Kazandjian, Dickran , Kelloff, Gary J. , Kremer, Brandon E. , Lightbody, Elizabeth D. , Lomas, Oliver , Mateos, María‐Victoria , de, Rocío Montes , Mukundan, Lata , Munshi, Nikhil C. , O’Donnell, Elizabeth , Paiva, Bruno , Patel, Reshma, Pugh, Trevor J. , Ramasamy, Karthik , Ray, Jill, Roshal, Mikhail , Ross, Jeremy A. , Sigman, Caroline C. , Thoren, Katie , Trudel, Suzanne , Ulaner, Gary A. , Valente, Nancy, Weiss, Brendan M. , Zamagni, Elena , Kumar, Shaji , Adam, Stacey J , Anderson, Melissa , Bustoros, Mark , Chapman, Jessica , Connors, Dana E , Dash, Ajeeta B , Di Bacco, Alessandra , Flores-Montero, Juan , Gay, Francesca , Hillengass, Jens , Landgren, C Ola , Lomas, Oliver C , Montes de Oca, Rocio , Pugh, Trevor J , Ramasamy, Karthik , Sigman, Caroline C , Thoren, Katie L , Paiva, Bruno , Ghobrial, Irene M , Ulaner, Gary , Gormley, Nicole , Anderson, Kenneth C. , Avet‐Loiseau, Hervé , Facon, Thierry T.F. , Gay, Francesca , Kirsch, Ilan R. , Landgren, Ola , Lonial, Sagar , Órfão, Alberto , Patel, Reshma, Zamagni, Elena

Mayo Clinic

Clinical Cancer Research | July 28, 2021 | Volume: 27 | Issue: 19 | Pages: 5195-5212

10.1158/1078-0432.ccr-21-1059 | PMID 34321279 Get It

AbstractThe development of novel agents has transformed the treatment paradigm for multiple myeloma, with minimal residual disease (MRD) negativity now achievable across the entire disease spectrum. Bone marrow–based technologies to assess MRD, including approaches using next-generation flow and next-generation sequencing, have provided real-time clinical tools for the sensitive detection and monitoring of MRD in patients with multiple myeloma. Complementary liquid biopsy–based assays are now quickly progressing with some, such as mass spectrometry methods, being very close to clinical use, while others utilizing nucleic acid–based technologies are still developing and will prove important to further our understanding of the biology of MRD. On the regulatory front, multiple retrospective individual patient and clinical trial level meta-analyses have already shown and will continue to assess the potential of MRD as a surrogate for patient outcome. Given all this progress, it is not surprising that a number of clinicians are now considering using MRD to inform real-world clinical care of patients across the spectrum from smoldering myeloma to relapsed refractory multiple myeloma, with each disease setting presenting key challenges and questions that will need to be addressed through clinical trials. The pace of advances in targeted and immune therapies in multiple myeloma is unprecedented, and novel MRD-driven biomarker strategies are essential to accelerate innovative clinical trials leading to regulatory approval of novel treatments and continued improvement in patient outcomes.
Impact of Atrial Fibrillation on Outcome in Takotsubo Syndrome: Data From the International Takotsubo Registry
El‐Battrawy, Ibrahim , Cammann, Victoria L. , Szawan, Konrad A. , Vece, Davide Di , Rossi, Aurelio, Wischnewsky, Manfred , Hermes‐Laufer, Julia , Gili, Sebastiano , Citro, Rodolfo , Franke, Jennifer , Meder, Benjamin , Knorr, Maike, Heiner, Susanne, Burgdorf, Christof , Kherad, Behrouz , Tschöpe, Carsten , Sarcon, Annahita, Shinbane, Jerold S., Rajan, Lawrence, Michels, Guido, Pfister, Roman , Cuneo, Alessandro , Jacobshagen, Claudius, Karakas, Mahir , Köenig, Wolfgang , Pott, Alexander , Meyer, Philippe , Arroja, José David , Banning, Adrian , Cuculi, Florim , Fischer, Thomas, Vasankari, Tuija , Napp, L. Christian , Budnik, Monika , Dworakowski, Rafał , MacCarthy, Philip , Osswald, Stefan , Galiuto, Leonarda , Chan, Christina , Bridgman, Paul , Beug, Daniel , Gilyarova, Ekaterina, Gilyarov, Mikhail , Kozel, Martin , Winchester, David E. , Ukena, Christian , Carrilho‐Ferreira, Pedro , Hauck, Christian , Paolini, Carla , Bilato, Claudio , Kobayashi, Yoshio, Rihal, Charanjit S. , Liu, Kan , Bianco, Matteo , Jörg, Lucas, Rickli, Hans , Böhm, Michael , Pinto, Fausto J. , Widimský, Petr , Felix, Stephan B. , Opolski, Grzegorz , Rottbauer, Wolfgang , Pieske, Burkert , Katus, Hugo A. , Münzel, Thomas , Crea, Filippo , Lüscher, Thomas F. , Duru, Fırat , Borggrefe, Martin, Ghadri, Jelena R. , Akın, İbrahim , Templin, Christian , Crea, Filippo , Citro, Rodolfo , El-Battrawy, Ibrahim , Duru, Firat , Tschöpe, Carsten , Koenig, Wolfgang , Meyer, Philippe , Banning, Adrian , Gilyarov, Mikhail , Ukena, Christian , Bilato, Claudio , Bianco, Matteo , Kato, Ken , Bossone, Eduardo , Neuhaus, Michael, Jaguszewski, Miłosz , Noutsias, Michel , D’Ascenzo, Fabrizio , Dichtl, Wolfgang , Kobza, Richard , Airaksinen, Juhani , Kaiser, Christoph A. , Delmas, Clément , Lairez, Olivier , Shilova, Alexandra S. , Toušek, Petr , Gałuszka, Jan , Poglajen, Gregor , Prasad, Abhiram , Rihal, Charanjit S. , Schulze, Paul Christian , Pestana, Gonçalo , Nguyen, Thanh Ha Tuan , Maier, Lars S. , Braun-Dullaeus, Ruediger Christian , Hasenfuß, Gerd , Schunkert, Heribert , Thiele, Hölger , Bauersachs, Johann , Horowitz, John D. , Mario, Carlo Di , Bax, Jeroen J. , Ruschitzka, Frank T.

Mayo Clinic

Journal of the American Heart Association | July 28, 2021 | Volume: 10 | Issue: 15 | Pages: No page available

10.1161/jaha.119.014059 | PMID 34315238 Get It

Background Atrial fibrillation (AF) is a major risk factor for mortality. The prevalence, clinical correlates, and prognostic impact of AF in Takotsubo syndrome (TTS) have not yet been investigated in a large patient cohort. This study aimed to investigate the prevalence, clinical correlates, and prognostic impact of AF in patients with TTS. Methods and Results Patients with TTS were enrolled from the International Takotsubo Registry, which is a multinational network with 26 participating centers in Europe and the United States. Patients were dichotomized according to the presence or absence of AF at the time of admission. Of 1584 patients with TTS, 112 (7.1%) had AF. The mean age was higher ( P <0.001), and there were fewer women ( P =0.046) in the AF than in the non‐AF group. Left ventricular ejection fraction was significantly lower ( P =0.001), and cardiogenic shock was more often observed ( P <0.001) in the AF group. Both in‐hospital ( P <0.001) and long‐term mortality ( P <0.001) were higher in the AF group. Multivariable Cox regression analysis revealed that AF was independently associated with higher long‐term mortality (hazard ratio, 2.31; 95% CI, 1.50–3.55; P <0.001). Among patients with AF on admission, 42% had no known history of AF before the acute TTS event, and such patients had comparable in‐hospital and long‐term outcomes compared with those with a history of AF. Conclusions In patients presenting with TTS, AF on admission is significantly associated with increased in‐hospital and long‐term mortality rates. Whether antiarrhythmics and/or cardioversion are beneficial in TTS with AF should thus be tested in a future trial. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01947621.
Cf‐02, a novel benzamide‐linked small molecule, blunts NF‐κB activation and NLRP3 inflammasome assembly and improves acute onset of accelerated and severe lupus nephritis in mice
Yang, Shin‐Ruen , Yang, Chih‐Yu , Chen, Ann , Weng, Jui‐Chun, Wan, Chih‐Jun, Wu, Chung‐Yao, Lee, Chia‐Chung, Chan, Jia‐Feng, Hsu, Yu‐Juei , Wu, Chia‐Chao , Huang, Hsu‐Shan , Liu, Feng‐Cheng , Ka, Shuk‐Man , Chen, Ann , Huang, Hsu-Shan , Liu, Feng-Cheng , Ka, Shuk-Man , Hua, Kuo‐Feng , Weng, Jui‐Chun, Tsai, Yu‐Ling , Wu, Chung-Yao, Hsieh, Chih‐Yu , Mukhopadhyay, Debabrata

Mayo Clinic

The FASEB Journal | July 27, 2021 | Volume: 35 | Issue: 8 | Pages: No page available

10.1096/fj.202100047r | PMID 34314075 Get It

Abstract In the present study, acute onset of severe lupus nephritis was successfully treated in mice using a new, benzamide‐linked, small molecule that targets immune modulation and the NLRP3 inflammasome. Specifically, 6‐(2,4‐difluorophenyl)‐3‐(3‐(trifluoromethyl)phenyl)‐2H‐benzo[e][1,3]oxazine‐2,4(3H)‐dione (Cf‐02) (a) reduced serum levels of IgG anti‐dsDNA, IL‐1β, IL‐6, and TNF‐α, (b) inhibited activation of dendritic cells and differentially regulated T cell functions, and (c) suppressed the NF‐κB/NLRP3 inflammasome axis, targeting priming and activating signals of the inflammasome. Moreover, treatment with Cf‐02 significantly inhibited secretion of IL‐1β in lipopolysaccharide‐stimulated macrophages, but this effect was abolished by autophagy induction. These results recommend Cf‐02 as a promising drug candidate for the serious renal conditions associated with systemic lupus erythematosus. Future investigations should examine whether Cf‐02 may also be therapeutic in other types of chronic kidney disease involving NLRP3 inflammasome‐driven signaling.
Breast and Prostate Cancer Risks for MaleBRCA1andBRCA2Pathogenic Variant Carriers Using Polygenic Risk Scores
Barnes, Daniel R. , Silvestri, Valentina , Leslie, Goska , McGuffog, Lesley, Yang, Xin , Adlard, Julian , Agnarsson, Bjarni A. , Ahmed, Munaza, Aittomäki, Kristiina, Andrulis, Irene L. , Arason, Aðalgeir , Azzollini, Jacopo , Barkardóttir, Rósa B. , Barrowdale, Daniel , Belotti, Muriel, Berthet, Pascaline, Boonen, Susanne E. , Borg, Åke , Brady, Angela F., Brewer, Carole, Brunet, Joan , Bucalo, Agostino, Caldés, Trinidad , Cassingham, Hayley , Christensen, Lise Lotte , Cini, Giulia , Claes, Kathleen , Collaborators, GEMO Study, Collaborators, EMBRACE, Cortesi, Laura , Damante, Giuseppe , Darder, Esther , Davidson, Rosemarie, Leeneer, Kim De , Putter, Robin De , Valle, Jesús Del , Ding, Yuan Chun , Donaldson, Alan , Eason, Jacqueline , Eeles, Rosalind A. , Engel, Christoph , Evans, D. Gareth , Feliubadaló, Lídia , Frone, Megan N. , Frost, Debra, Gehrig, Andrea, Giraud, Sophie , Glendon, Gord , Goldgar, David E. , Greene, Mark H. , Gregory, Helen , Groß, Eva, Hahnen, Eric, Hamann, Ute, Hansen, Thomas van Overeem , Hanson, Helen , Horváth, Judit , Investigators, KConFab, Investigators, HEBON, Izatt, Louise , James, Paul A. , Janavičius, Ramūnas , Jensen, Uffe Birk , Johannsson, Oskar T., John, Esther M. , Kramer, Gero , Kroeldrup, Lone , Kruse, Torben A. , Lautrup, Charlotte Kvist , López‐Fernández, Adrià , Mai, Phuong L, Manoukian, Siranoush , Mátrai, Zoltán , Matricardi, Laura , Mebirouk, Noura, Meindl, Alfons , Montagna, Marco , Monteiro, Álvaro N.A. , Morrison, Patrick J. , Muranen, Taru , Nathanson, Katherine L. , Niederacher, Dieter , Oláh, Edith , Olopade, Olufunmilayo I. , Pedersen, Inge Søkilde , Peissel, Bernard , Peterlongo, Paolo , Petersen, Annabeth Høgh , Pinto, Pedro, Porteous, Mary, Pottinger, Caroline , Pujana, Miquel Angel, Ramser, Juliane, Rantala, Johanna, Rogers, Mark T., Rønlund, Karina, Abajo, A.M. SÁnchez De, Shah, Payal D. , Sharif, Saba , Side, Lucy, Stadler, Zsofia, Steele, Linda , Sutter, Christian , Tan, Yen Y. , Teixeira, Manuel R. , Teulé, Àlex , Thull, Darcy L. , Trainer, Alison H., Tripathi, Vishakha , Valentini, Virginia , Viel, Alessandra , Walker, Lisa, Wang‐Gohrke, Shan , Wappenschmidt, Barbara , Whaite, Anna , Offit, Kenneth, Thomassen, Mads , Schmutzler, Rita K., Simard, Jacques , Easton, Douglas F. , Chenevix‐Trench, Georgia , Antoniou, Antonis C. , Pujana, Miguel Ángel , Dennis, Joe , Yang, Xin , Adlard, Julian , Agnarsson, Bjarni A , Andrulis, Irene L , Arason, Adalgeir , Arnold, Norbert , Auber, Bernd , Azzollini, Jacopo , Barkardottir, Rosa B , Barrowdale, Daniel , Benitez, Javier , Boonen, Susanne E , Bozsik, Aniko , Brennan, Paul , Brunet, Joan , Bucalo, Agostino , Caligo, Maria A , Campbell, Ian G , Cassingham, Hayley , Cini, Giulia , Claes, Kathleen B M , Coppa, Anna , Cortesi, Laura , Darder, Esther , de la Hoya, Miguel , de Putter, Robin , Del Valle, Jesús , Domchek, Susan M , Donaldson, Alan , Eason, Jacqueline , Engel, Christoph , Fostira, Florentia , Frone, Megan , Glendon, Gord , Godwin, Andrew K. , Greene, Mark H , Hahnen, Eric , Hanson, Helen , Izatt, Louise , Izquierdo, Angel , James, Paul , John, Esther M , Kroeldrup, Lone , Kruse, Torben A , Lazaro, Conxi , Lesueur, Fabienne , Matrai, Zoltan , Montagna, Marco , Monteiro, Alvaro N , Morrison, Patrick J , Muranen, Taru A , Nathanson, Katherine L , Neuhausen, Susan L. , Nevanlinna, H , Nguyen-Dumont, Tu , Niederacher, Dieter , Palli, Domenico , Parsons, Michael T , Perez-Segura, Pedro , Peterlongo, Paolo , Pinto, Pedro , Pottinger, Caroline , Radice, Paolo , Robson, Mark , Rump, Andreas , Sharif, Saba , Steele, Linda , Stoppa-Lyonnet, Dominique , Teixeira, Manuel R , Thull, Darcy L , Tischkowitz, Marc D. , Toland, Amanda Ewart , Tommasi, Stefania , Toss, Angela , Tripathi, Vishakha , Valentini, Virginia , van Asperen, Christi J , Venturelli, Marta , Viel, Alessandra , Joseph, Vijai , Whaite, Anna , Simard, Jacques , Easton, Doug , Chenevix-Trench, Georgia , Ottini, Laura , Barnes, Daniel R , Leslie, Goska , Pujana, Miquel Angel , Eeles, Rosalind A , Evans, D Gareth , Matricardi, Laura , Olopade, Olufunmilayo I , Silvestri, Valentina , De Leeneer, Kim , Feliubadaló, Lidia , Hansen, Thomas van Overeem , Manoukian, Siranoush , Arnold, Norbert , Auber, Bernd , Balmañà, Judith , Barwell, Julian , Benı́tez, Javier , Bozsik, Anikó , Brady, Angela F., Buys, Saundra S. , Caligo, Maria A. , Campbell, Ian , Collaborators, GEMO Study, Collaborators, EMBRACE, Cook, Jackie A , Hoya, Miguel de la , Dı́ez, Orland , Domchek, Susan M. , Gallagher, David James , Hentschel, Julia , Investigators, KConFab, Investigators, HEBON, Izquierdo, Á. , Lázaro, Conxi , Lesueur, Fabienne , Mai, Phuong L, Maxwell, Kara N. , Meindl, Alfons , Nevanlinna, Heli , Nguyen‐Dumont, Tú , Palli, Domenico , Parsons, Michael T. , Radice, Paolo , Robson, Mark E. , Rump, Andreas , Singer, Christian F. , Stoppa‐Lyonnet, Dominique , Asperen, Christi J. van , Vijai, Joseph , Zanna, Ines , Couch, Fergus J. , Ottini, Laura

Mayo Clinic

JNCI: Journal of the National Cancer Institute | July 26, 2021 | Volume: 114 | Issue: 1 | Pages: 109-122

10.1093/jnci/djab147 | PMID 34320204 Get It

AbstractBackgroundRecent population-based female breast cancer and prostate cancer polygenic risk scores (PRS) have been developed. We assessed the associations of these PRS with breast and prostate cancer risks for male BRCA1 and BRCA2 pathogenic variant carriers.Methods483 BRCA1 and 1318 BRCA2 European ancestry male carriers were available from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). A 147-single nucleotide polymorphism (SNP) prostate cancer PRS (PRSPC) and a 313-SNP breast cancer PRS were evaluated. There were 3 versions of the breast cancer PRS, optimized to predict overall (PRSBC), estrogen receptor (ER)–negative (PRSER-), or ER-positive (PRSER+) breast cancer risk.ResultsPRSER+ yielded the strongest association with breast cancer risk. The odds ratios (ORs) per PRSER+ standard deviation estimates were 1.40 (95% confidence interval [CI] =1.07 to 1.83) for BRCA1 and 1.33 (95% CI = 1.16 to 1.52) for BRCA2 carriers. PRSPC was associated with prostate cancer risk for BRCA1 (OR = 1.73, 95% CI = 1.28 to 2.33) and BRCA2 (OR = 1.60, 95% CI = 1.34 to 1.91) carriers. The estimated breast cancer odds ratios were larger after adjusting for female relative breast cancer family history. By age 85 years, for BRCA2 carriers, the breast cancer risk varied from 7.7% to 18.4% and prostate cancer risk from 34.1% to 87.6% between the 5th and 95th percentiles of the PRS distributions.ConclusionsPopulation-based prostate and female breast cancer PRS are associated with a wide range of absolute breast and prostate cancer risks for male BRCA1 and BRCA2 carriers. These findings warrant further investigation aimed at providing personalized cancer risks for male carriers and informing clinical management.
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA
Miguel, Jesús F. San , Usmani, Saad Z. , Paiva, Bruno , Plesner, Torben , Hungria, Vânia , Moreau, Philippe , Mateos, María‐Victoria , Perrot, Aurore , Iida, Shinsuke , Kumar, Shaji , Donk, Niels W.C.J. van de , Sonneveld, Pieter , Spencer, Andrew , Krevvata, Maria, Heuck, Christoph, Wang, Jianping , Ukropec, Jon, Kobos, Rachel, Sun, Steven , Qi, Mia, Munshi, Nikhil C. , San-Miguel, Jesus , Paiva, Bruno , Hungria, Vania , Mateos, María-Victoria , Perrot, Aurore , Iida, Shinsuke , Kumar, Shaji K , Moreau, Philippe , Usmani, Saad , Cavo, Michèle , Weisel, Katja C , Dimopoulos, Meletios Α. , Avet‐Loiseau, Hervé , Bahlis, Nizar Jacques , Facon, Thierry T.F.

Mayo Clinic

Blood | July 21, 2021 | Volume: 139 | Issue: 6 | Pages: 835-844

10.1182/blood.2021011101 | PMID 34289038 Get It

Abstract We explored minimal residual disease (MRD) in relapsed/refractory multiple myeloma (RRMM) and transplant-ineligible (TIE) newly diagnosed multiple myeloma (NDMM) using data from 4 phase 3 studies (POLLUX, CASTOR, ALCYONE, and MAIA). Each study previously demonstrated that daratumumab-based therapies improved MRD negativity rates and reduced the risk of disease progression or death by approximately half vs standards of care. We conducted a large-scale pooled analysis for associations between patients achieving complete response or better (≥CR) with MRD-negative status and progression-free survival (PFS). MRD was assessed via next-generation sequencing (10−5 sensitivity threshold). Patient-level data were pooled from all 4 studies and for patients with TIE NDMM and patients with RRMM who received ≤2 prior lines of therapy (≤2 PL). PFS was evaluated by response and MRD status. Median follow-up (months) was 54.8 for POLLUX, 50.2 for CASTOR, 40.1 for ALCYONE, and 36.4 for MAIA. Patients who achieved ≥CR and MRD negativity had improved PFS vs those who failed to reach CR or were MRD positive (TIE NDMM and RRMM hazard ratio [HR] 0.20, P &lt; .0001; TIE NDMM and RRMM ≤2 PL HR 0.20, P &lt; .0001). This benefit occurred irrespective of therapy or disease setting. A time-varying Cox proportional hazard model confirmed that ≥CR with MRD negativity was associated with improved PFS. Daratumumab-based treatment was associated with more patients reaching ≥CR and MRD negativity. These findings represent the first large-scale analysis with robust methodology to support ≥CR with MRD negativity as a prognostic factor for PFS in RRMM and TIE NDMM. These trials were registered at www.clinicaltrials.gov as #NCT02076009, #NCT02136134, #NCT02195479, and #NCT02252172.
Prenatal Diethylstilbestrol Exposure and Cancer Risk in Males
Strohsnitter, William C. , Hyer, Marianne , Titus, Linda , Romero, Iris L. , Huo, Dezheng , Hoover, Robert N. , Hatch, Elizabeth E , Titus, Linda , Romero, Iris L , Troisi, Rebecca , Bertrand, Kimberly A. , Cheville, Andrea , Palmer, Julie R. , Aagaard, Kjersti Marie

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | July 16, 2021 | Volume: 30 | Issue: 10 | Pages: 1826-1833

10.1158/1055-9965.epi-21-0234 | PMID 34272263 Get It

Abstract Background: The influence of prenatal diethylstilbestrol (DES) exposure on cancer incidence among middle-aged men has not been well-characterized. We investigated whether exposure to DES before birth impacts overall cancer risk, and risk of site-specific cancers. Methods: Men (mean age in 2016 = 62.0 years) who were or were not prenatally DES exposed were identified between 1953 and 1994 and followed for cancer primarily via questionnaire approximately every 5 years between 1994 and 2016. The overall and site-specific cancer rates of the two groups were compared using Poisson regression and proportional hazards modeling with adjustment for age. Results: DES exposure was not associated with either overall cancer [hazard ratio (HR), 0.94; 95% confidence interval (CI), 0.77–1.15] or total prostate cancer rates (HR, 0.95; 95% CI, 0.68–1.33), but was inversely associated with urinary tract cancer incidence (HR, 0.48; 95% CI, 0.23–1.00). Conclusions: There was no increase in either overall or prostate cancer rates among men prenatally DES exposed relative to those unexposed. An unexpected risk reduction was observed for urinary system cancers among the exposed relative to those unexposed. These findings suggest that prenatal DES exposure is unlikely to be an important contributor to cancer development in middle-aged men. Impact: The results of this study could lend reassurance to middle-aged men who were prenatally DES exposed that their exposure does not adversely influence their overall cancer risk.